Showing 1-  of  Publications
m6A mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade.
By Product Type
By Research Area
Images See all
Immunofluorescent analysis of (4% PFA) fixed human tonsillitis tissue using PD-1/CD279 mouse mAb (66220-1-Ig) at dilution of 1:50 and CD20 rabbit pAb (24828-1-AP) at dilution of 1:50, further stained with Alexa Fluor 488-conjugated AffiniPure Goat Anti-Mouse IgG(H+L) for 66220-1-Ig, and Alexa Fluor 594-conjugated AffiniPure Goat Anti-Rabbit IgG (H+L) for 24828-1-AP
Programmed cell death 1 (PD-1, also known as CD279) is an immunoinhibitory receptor that belongs to the CD28/CTLA-4 subfamily of the Ig superfamily. It is a 288 amino acid (aa) type I transmembrane protein composed of one Ig superfamily domain, a stalk, a transmembrane domain, and an intracellular domain containing an immunoreceptor tyrosine-based inhibitory motif (ITIM) as well as an immunoreceptor tyrosine-based switch motif (ITSM) (PMID: 18173375). PD-1 is expressed during thymic development and is induced in a variety of hematopoietic cells in the periphery by antigen receptor signaling and cytokines (PMID: 20636820). Engagement of PD-1 by its ligands PD-L1 or PD-L2 transduces a signal that inhibits T-cell proliferation, cytokine production, and cytolytic function (PMID: 19426218). It is critical for the regulation of T cell function during immunity and tolerance. Blockade of PD-1 can overcome immune resistance and also has been shown to have antitumor activity (PMID: 22658127; 23169436). The calculated molecular weight of PD-1 is 32 kDa. It has been reported that PD-1 is heavily glycosylated and migrates with an apparent molecular mass of 47-55 kDa on SDS-PAGE (PMID: 8671665; 17640856; 17003438).